Innovative Genetic Testing Geneus Health offers the patented GARS test, which uniquely predicts vulnerability to addictive, impulsive, and compulsive behaviors, presenting a compelling value proposition for healthcare providers and clinics focused on behavioral health and addiction treatment.

Growing Market Presence Following its acquisition by Ivitalize in 2021, Geneus Health has expanded its operational footprint in San Antonio, signaling increased capacity and potential for market penetration within the genetic testing and wellness sectors.

Market Opportunity With an estimated revenue between 1 million and 10 million and a specialized focus on addiction-related genetic testing, Geneus Health offers opportunities to collaborate with mental health clinics, substance abuse programs, and personalized medicine providers.

Technology Integration Utilizing advanced analytics and web technologies such as Snowplow and Google Analytics, Geneus Health demonstrates a strong digital presence that can facilitate targeted outreach and engagement with health providers interested in genetic testing solutions.

Industry Alignment As a healthcare company operating within the wellness and genetics space, Geneus Health aligns well with the growing demand for personalized health assessments, opening avenues for partnerships with biotech firms, health insurers, and wellness centers seeking innovative behavioral health solutions.